Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
about
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisUltrasound in juvenile idiopathic arthritisTreatment of juvenile idiopathic arthritis: a revolution in careWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?Current and emerging strategies for the prevention of graft-versus-host diseaseThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisNew pharmacological strategies in rheumatic diseasesJuvenile Idiopathic Arthritis: Diagnosis and TreatmentJuvenile Idiopathic Arthritis in the Era of International Cooperation.2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Role of podocyte B7-1 in diabetic nephropathyInvestigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.Polyarticular juvenile idiopathic arthritis - epidemiology and management approachesA phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Juvenile idiopathic arthritis-associated uveitis.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.The development and assessment of biological treatments for children.Current medical treatments for juvenile idiopathic arthritis.Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.Systemic arthritis in children: a review of clinical presentation and treatmentChildhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritisTrial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosisUpdate on the treatment of juvenile idiopathic arthritisDisease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritisTocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.Using registries to identify adverse events in rheumatic diseases.Challenges in the management of juvenile idiopathic arthritis with etanercept
P2860
Q24610145-5DACD051-E2EC-43DD-B5A0-F4FA52A1ECDCQ26745505-F053D239-3BD7-427A-8A46-A6D40137150DQ26849497-41C5EB48-1448-4206-97D6-B6E755110CAFQ26995394-FA3FC676-1D3F-4EE4-9C85-3BC4B0F4BCB1Q27016541-3145DA6A-CD0B-4AFA-AF87-B53F5D7CD809Q27025862-3C6AA1D0-A940-4157-A411-8EACCAFF247AQ28073763-0D1DEB70-4890-4C41-99BD-F968061DF30AQ28079246-B25A8DD6-8863-45C2-A79C-6193182E5CCCQ30235998-1F58761F-C324-4552-A15C-1E2A182B75E1Q33613293-E9F2BE4A-54CC-4211-98E8-EF82ED24862CQ33659233-5B98C926-E3CE-4718-94E7-E184FF6BA3D5Q33765738-8F83DAB8-56B1-42A0-BF0C-7F8E3844C5A6Q33814864-77F56B40-7F3D-41E1-9EC7-AB7E1D345F26Q33849223-815AAA6F-902C-4AC0-8C89-E9CC4FAF1DC5Q34080132-7050E366-669C-4FCB-ADA0-8CCC071E3703Q34082857-2C239EA0-C808-48EF-93A0-9CCB2861EB32Q34157346-40C813E1-E736-4AB3-B3CD-50E7EB7447A6Q34196943-C23A00B0-F8A0-429E-A662-C14FB6517A59Q34434750-DDB34E9E-6E7D-41DF-810B-04EF03814105Q34632661-854A3D43-5E17-44A0-BC04-1F9B0E99B9FBQ34950552-ECA4D969-639D-4C1A-8199-88101953A949Q35041117-F63A1CF0-35CE-448B-97B5-D7BB5C562851Q35135936-80E6C781-DA7A-4BFC-9779-C2ECB7203ADAQ35294398-F084664D-8C11-4709-B8C8-98B00FCA719EQ35561106-F1659B79-F29B-4730-8618-EAAD8053BC1AQ35567870-958F32D2-0927-4C57-9C59-D5F9A671A179Q35605487-4FC7F0E7-8149-486C-A3F9-35C1520E4D59Q35659928-150FEA69-FFA7-44F3-A505-7F89E93D90DFQ35743755-9F0B5208-ABB4-4F16-96A5-52A30D441749Q35870808-381A89D8-2B46-4AAE-90F3-F4CFED5DD3F1Q35926593-5F5158AA-29D5-4E73-8919-3772FB2F6CADQ36292592-FB3838B5-3131-46C3-9137-B0DB0E23C3E4Q36435134-078CDA3A-E8BA-4ED7-9622-85E7C7400976Q36542397-E1233A50-9FBD-4313-A461-F6AD62F6A079Q37060351-4E62B178-8839-4DA4-8C10-BE8767D2F8A3Q37147226-51D165DE-22E0-4433-84D7-51BB4BF5BC49Q37207120-E9A296AA-53B9-402D-BA4E-7261AE4B6D4DQ37235737-440B5CA1-F25A-450D-B780-A50F2BC4D032Q37268816-BEB29DC4-FD23-4C95-A4AB-A46D144E0362Q37303219-93734491-224E-4366-85E3-84EA65614999
P2860
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Abatacept in children with juv ...... o-controlled withdrawal trial.
@ast
Abatacept in children with juv ...... o-controlled withdrawal trial.
@en
Abatacept in children with juv ...... o-controlled withdrawal trial.
@nl
type
label
Abatacept in children with juv ...... o-controlled withdrawal trial.
@ast
Abatacept in children with juv ...... o-controlled withdrawal trial.
@en
Abatacept in children with juv ...... o-controlled withdrawal trial.
@nl
prefLabel
Abatacept in children with juv ...... o-controlled withdrawal trial.
@ast
Abatacept in children with juv ...... o-controlled withdrawal trial.
@en
Abatacept in children with juv ...... o-controlled withdrawal trial.
@nl
P2093
P50
P1433
P1476
Abatacept in children with juv ...... o-controlled withdrawal trial.
@en
P2093
Alan J Block
Alberto Martini
Allison Covucci
Carlos Abud-Mendoza
Carol A Wallace
Christine Hom
Claudia Goldenstein-Schainberg
Claudia Saad-Magalhães
Clovis A Silva
Daniel J Lovell
P304
P356
10.1016/S0140-6736(08)60998-8
P407
P577
2008-07-14T00:00:00Z